{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T17:57:53Z","timestamp":1771783073924,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,22]]},"DOI":"10.7759\/cureus.104069","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T16:59:24Z","timestamp":1771779564000},"source":"Crossref","is-referenced-by-count":0,"title":["Timing and Resolution of Bothersome Hot Flashes Following Short Course Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix, and Stereotactic Body Radiotherapy for Localized Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Sarthak","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukhjeevan","family":"Nijhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Sowmiyanarayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malika T","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan L","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D","family":"Leger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Suy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Comprehensive Cancer Network.\u00a0Prostate Cancer (Version 1.2025). (2025). Accessed. Feburuary 16, 2025: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","unstructured":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer. an individual patient data meta-analysis. Kishan, Amar U et al. The Lancet Oncology, Volume. 23:304-16. 10.1016\/S1470-2045(21)00705-1","journal-title":"Kishan, Amar U et al. The Lancet Oncology, Volume"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.06.009","article-title":"The relationship between hot flashes and testosterone recovery after 12 months of androgen suppression for men with localised prostate cancer in the ascende-RT trial","volume":"29","author":"Dosani M","year":"2017","unstructured":"Dosani M, Morris WJ, Tyldesley S, Pickles T. The relationship between hot flashes and testosterone recovery after 12 months of androgen suppression for men with localised prostate cancer in the ascende-RT trial. Clin Oncol (R Coll Radiol). 2017, 29:696-701. 10.1016\/j.clon.2017.06.009","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2018.03.002","article-title":"Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experience","volume":"10","author":"Challapalli A","year":"2018","unstructured":"Challapalli A, Edwards SM, Abel P, Mangar SA. Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a single institution experience. Clin Transl Radiat Oncol. 2018, 10:29-35. 10.1016\/j.ctro.2018.03.002","journal-title":"Clin Transl Radiat Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44440","article-title":"Testosterone as a biomarker for quality of life (qol) following androgen deprivation therapy (adt) and stereotactic body radiotherapy (SBRT)","volume":"15","author":"Shah S","year":"2023","unstructured":"Shah S, Pepin A, Forsthoefel M, et al.. Testosterone as a biomarker for quality of life (qol) following androgen deprivation therapy (adt) and stereotactic body radiotherapy (SBRT). Cureus. 2023, 15:e44440. 10.7759\/cureus.44440","journal-title":"Cureus"},{"key":"ref6","article-title":"Estrogenic side effects of androgen deprivation therapy","volume":"9","author":"Guise TA","year":"2007","unstructured":"Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR. Estrogenic side effects of androgen deprivation therapy. Rev Urol. 2007, 9:163-80.","journal-title":"Rev Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2011.101","article-title":"Androgen deprivation therapy-associated vasomotor symptoms","volume":"14","author":"Jones JM","year":"2012","unstructured":"Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012, 14:193-37. 10.1038\/aja.2011.101","journal-title":"Asian J Androl"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31015","article-title":"Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia","volume":"124","author":"Gonzalez BD","year":"2018","unstructured":"Gonzalez BD, Small BJ, Cases MG, et al.. Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer. 2018, 124:499-506. 10.1002\/cncr.31015","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1188\/19.ONF.E107-E118","article-title":"Management of androgen deprivation therapy-associated hot flashes in men with prostate cancer","volume":"46","author":"Qan'ir Y","year":"2019","unstructured":"Qan'ir Y, DeDeaux D, Godley PA, Mayer DK, Song L. Management of androgen deprivation therapy-associated hot flashes in men with prostate cancer. Oncol Nurs Forum. 2019, 46:E107-18. 10.1188\/19.ONF.E107-E118","journal-title":"Oncol Nurs Forum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford ED","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, et al.. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019, 22:24-38. 10.1038\/s41391-018-0079-0","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone recovery following androgen suppression and prostate radiotherapy (transport): a pooled analysis of five randomized trials from the meta-analysis of randomized trials in cancer of the prostate (MARCAP) Consortium","volume":"87","author":"Ong WL","year":"2025","unstructured":"Ong WL, Romero T, Roy S, et al.. Testosterone recovery following androgen suppression and prostate radiotherapy (transport): a pooled analysis of five randomized trials from the meta-analysis of randomized trials in cancer of the prostate (MARCAP) Consortium. Eur Urol. 2025, 87:49-57. 10.1016\/j.eururo.2024.09.009","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial","volume":"143","author":"Nabid A","year":"2021","unstructured":"Nabid A, Carrier N, Vigneault E, et al.. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. Eur J Cancer. 2021, 143:64-74. 10.1016\/j.ejca.2020.10.023","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.11.045","article-title":"Long-term pulmonary outcomes of a feasibility study of inverse-planned, multibeam intensity modulated radiation therapy in node-positive breast cancer patients receiving regional nodal irradiation","volume":"103","author":"Ho AY","year":"2019","unstructured":"Ho AY, Ballangrud A, Li G, et al.. Long-term pulmonary outcomes of a feasibility study of inverse-planned, multibeam intensity modulated radiation therapy in node-positive breast cancer patients receiving regional nodal irradiation. Int J Radiat Oncol Biol Phys. 2019, 103:1100-8. 10.1016\/j.ijrobp.2018.11.045","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31024","article-title":"Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia","volume":"124","author":"Gonzalez BD","year":"2018","unstructured":"Gonzalez BD, Small BJ, Cases MG, Williams NL, Fishman MN, Jacobsen PB, Jim HS. Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer. 2018, 124:499-506. 10.1002\/cncr.31024","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.06.017","article-title":"Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer","volume":"180","author":"Gulley JL","year":"2008","unstructured":"Gulley JL, Aragon-Ching JB, Steinberg SM, et al.. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2008, 180:1432-7; discussion 1437. 10.1016\/j.juro.2008.06.017","journal-title":"J Urol"},{"key":"ref16","article-title":"The type of ADT may matter for testosterone recovery","volume":"28","author":"Moul JW","year":"2021","unstructured":"Moul JW. The type of ADT may matter for testosterone recovery. Can J Urol. 2021, 28:10743.","journal-title":"Can J Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01105-0","article-title":"Relugolix: first global approval","volume":"79","author":"Markham A","year":"2019","unstructured":"Markham A. Relugolix: first global approval. Drugs. 2019, 79:675-79. 10.1007\/s40265-019-01105-0","journal-title":"Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1289249","article-title":"Early biochemical outcomes following neoadjuvant\/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer","volume":"13","author":"Gallagher L","year":"2023","unstructured":"Gallagher L, Xiao J, Hsueh J, et al.. Early biochemical outcomes following neoadjuvant\/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. Front Oncol. 2023, 13:1289249. 10.3389\/fonc.2023.1289249","journal-title":"Front Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.7279","article-title":"Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer","volume":"10","author":"Spratt DE","year":"2024","unstructured":"Spratt DE, George DJ, Shore ND, et al.. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncol. 2024, 10:594-602. 10.1001\/jamaoncol.2023.7279","journal-title":"JAMA Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore ND","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, et al.. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020, 382:2187-96. 10.1056\/NEJMoa2004325","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.09.007","article-title":"Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study","volume":"84","author":"Tombal B","year":"2023","unstructured":"Tombal B, Collins S, Morgans AK, et al.. Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study. Eur Urol. 2023, 84:579-87. 10.1016\/j.eururo.2023.09.007","journal-title":"Eur Urol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.09.010","article-title":"Quantitative analysis of serial positron emission tomography imaging in men with metastatic castration-resistant prostate cancer treated with enzalutamide","volume":"7","author":"Gandhy SU","year":"2024","unstructured":"Gandhy SU, Karzai FH, Bilusic M, et al.. Quantitative analysis of serial positron emission tomography imaging in men with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur Urol Oncol. 2024, 7:735-41. 10.1016\/j.euo.2023.09.010","journal-title":"Eur Urol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55729","article-title":"Bothersome hot flashes following neoadjuvant androgen deprivation therapy and stereotactic body radiotherapy for localized prostate cancer","volume":"16","author":"Shah S","year":"2024","unstructured":"Shah S, Pepin A, Jatar S, et al.. Bothersome hot flashes following neoadjuvant androgen deprivation therapy and stereotactic body radiotherapy for localized prostate cancer. Cureus. 2024, 16:e55729. 10.7759\/cureus.55729","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico AV","year":"1998","unstructured":"D'Amico AV, Whittington R, Malkowicz SB, et al.. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998, 280:969-74. 10.1001\/jama.280.11.969","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience","volume":"8","author":"Chen LN","year":"2013","unstructured":"Chen LN, Suy S, Uhm S, et al.. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013, 8:58. 10.1186\/1748-717X-8-58","journal-title":"Radiat Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00127","article-title":"Galectin-3 determines tumor cell adaptive strategies in stressed tumor microenvironments","volume":"6","author":"Cardoso AC","year":"2016","unstructured":"Cardoso AC, Andrade LN, Bustos SO, Chammas R. Galectin-3 determines tumor cell adaptive strategies in stressed tumor microenvironments. Front Oncol. 2016, 6:127. 10.3389\/fonc.2016.00127","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-22","article-title":"CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures","volume":"3","author":"Oermann E","year":"2010","unstructured":"Oermann E, Collins BT, Erickson KT, et al.. CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures. J Hematol Oncol. 2010, 3:22. 10.1186\/1756-8722-3-22","journal-title":"J Hematol Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei JT","year":"2000","unstructured":"Wei JT, Dunn RL, Litwin MS, et al.. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000, 56:899-905. 10.1016\/S0090-4295(00)00858-X","journal-title":"Urology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index composite short form","volume":"85","author":"Skolarus TA","year":"2015","unstructured":"Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT. Minimally important difference for the Expanded Prostate Cancer Index composite short form. Urology. 2015, 85:101-105. 10.1016\/j.urology.2014.08.044","journal-title":"Urology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2011.01.011","article-title":"Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum","volume":"38","author":"Sajid S","year":"2011","unstructured":"Sajid S, Mohile SG, Szmulewitz R, Posadas E, Dale W. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin Oncol. 2011, 38:309-25. 10.1053\/j.seminoncol.2011.01.011","journal-title":"Semin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.10.082","article-title":"Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death","volume":"75","author":"D'Amico AV","year":"2009","unstructured":"D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys. 2009, 75:10-15. 10.1016\/j.ijrobp.2008.10.082","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06013.x","article-title":"Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer","volume":"97","author":"Murthy V","year":"2006","unstructured":"Murthy V, Norman AR, Shahidi M, et al.. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int. 2006, 97:476-79. 10.1111\/j.1464-410X.2006.06013.x","journal-title":"BJU Int"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group Phase 2 trial","volume":"78","author":"Dearnaley DP","year":"2020","unstructured":"Dearnaley DP, Saltzstein DR, Sylvester JE, et al.. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group Phase 2 trial. Eur Urol. 2020, 78:184-92. 10.1016\/j.eururo.2020.03.001","journal-title":"Eur Urol"},{"key":"ref34","article-title":"Testosterone recovery following short course androgen deprivation therapy and stereotactic body radiotherapy correlates closely with improvements in patient-reported hormonal and sexual domain scores","volume":"105","author":"Forsthoefel","unstructured":"Forsthoefel, MK, Burlile, J, Lane, SA, et. al. Testosterone recovery following short course androgen deprivation therapy and stereotactic body radiotherapy correlates closely with improvements in patient-reported hormonal and sexual domain scores. Int J Rad Oncol Bio Phy. 105:594.","journal-title":"Int J Rad Oncol Bio Phy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442182-timing-and-resolution-of-bothersome-hot-flashes-following-short-course-oral-gonadotropin-releasing-hormone-receptor-antagonist-relugolix-and-stereotactic-body-radiotherapy-for-localized-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T16:59:25Z","timestamp":1771779565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442182-timing-and-resolution-of-bothersome-hot-flashes-following-short-course-oral-gonadotropin-releasing-hormone-receptor-antagonist-relugolix-and-stereotactic-body-radiotherapy-for-localized-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.104069","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,22]]}}}